Imatinib-d8

• CAT Number: S000374
• CAS Number: 1092942-82-9
• Molecular Formula: C29H23D8N7O
• Molecular Weight: 501.65
• Purity: ≥95%
• IUPAC Name: N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]-4-[(2,2,3,3,5,5,6,6-octadeuterio-4-methylpiperazin-1-yl)methyl]benzamide
• InChI: InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)/i14D2,15D2,16D2,17D2
• InChIKey: KTUFNOKKBVMGRW-AZGHYOHESA-N
• SMILES: CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5

Imatinib-d8（Cat No.:S000374） is a deuterated form of imatinib, a medication widely used in the treatment of certain types of cancer, such as chronic myeloid leukemia and gastrointestinal stromal tumors. In this version, eight hydrogen atoms are replaced by deuterium. This substitution aims to investigate the drug’s pharmacokinetics and metabolism, offering insights into its stability and degradation pathways. By tracking the deuterium-labeled molecules, researchers can precisely follow imatinib’s distribution and interactions within the body, facilitating a better understanding of its therapeutic effects and potentially enhancing its clinical application.